Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=136 Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
N/A N=105 Cell Mediated Immunity in Older Adults
Immunity to Influenza Vaccine
Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
N/A N=66 Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
N/A N=88 Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Pneumococcal Infection
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the Quality of Antibodies After PNEUMOVAX and PREVNAR - Monocyte Module M4.15 — 1; 2; 0; 2…
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Phase 3 N=3,837 Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines. — 28.25…
Phase 4 N=768 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
Pertussis · Tetanus · Diphtheria
Primary: Percentage of Participants With Seroprotection Against Tetanus and Diphtheria Before and After Revaccination With ADACEL® 10 Years After a Previous Dose — 45; 49; 100…
Phase 2 N=98 Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
N/A N=77 Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Shingles
Primary: Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX — 44; 33 participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 2 N=729 Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 2 N=322 Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
Prevention of COVID-19
Primary: Antibody Titre Increase 14 Days After Study Vaccination Dose. — 100; 100; 78.46; 87.22 percentage of participants
Phase 2 N=601 Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Phase 4 N=241 Gene Signatures of Influenza Vaccine Responses in Older Adults
Influenza
Primary: Innate Cell IFNa2a Production — 112.3650; 131.4214; 107.5846; 134.9071 pg/mL
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
N/A N=174 Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Vaccine Response Impaired
Primary: Antibody Titer Responses to Hepatitis B Virus Surface Antigen (HBV sAg) Vaccine, Measured and Predicted Based on Pre-vaccination Biomarkers in Healthy, Elderly…
Phase 4 N=2,902 Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Influenza
Primary: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years — 315; 581; 697; 1048…
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
Phase 2 N=126 Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of TIV — 84; 53; 81…
Phase 3 N=1,539 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Influenza Immunization · Healthy Volunteers
Primary: Geometric Mean Titers (GMTs) of Influenza Antibodies in Participants Aged 60-64 Years and Greater Than or Equal to (>=) 65 Years — 471; 248; 303; 178 titers
Phase 3 N=1,534 A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
Herpes Zoster
Primary: Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group Ratios — 47434.82…
Phase 3 N=125 Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf — 17; 36; 95; 80…
Phase 3 N=2,100 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Influenza Immunization · Healthy Volunteers
Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28 — 309.0; 110.0; 540.0; 239.9 titers
Phase 3 N=2,680 Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
Influenza
Primary: 1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c — 60.7; 59.6; NA; 302.8 Titer
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 3 N=126 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: Percentages of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVc — 73; 58; 67; 45…